Biodexa Pharmaceuticals Plc (BDRX) stock profile

Frequently asked questions

What does Biodexa Pharmaceuticals Plc (BDRX) do?

Biodexa Pharmaceuticals Plc is a clinical-stage biopharmaceutical company focused on developing a pipeline of products for treating familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and rare or orphan cancers of the brain. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme currently in Phase II studies for treating Type 1 diabetes. The company is also developing MTX110, which is in Phase I studies for treating diffuse intrinsic pontine glioma, diffuse midline glioma, and medulloblastoma. Additionally, Biodexa offers drug delivery platforms including Q-Sphera, a polymer microsphere technology for sustained-release therapeutics; MidaSolve, an oligosaccharide nanotechnology that solubilizes drugs for direct liquid administration into tumors; and MidaCore, a gold nanoparticle for targeting disease sites with chemotherapeutic or immunotherapeutic agents. The company has collaboration agreements with Janssen and Melior. Formerly known as Midatech Pharma plc, the company changed its name to Biodexa Pharmaceuticals Plc in March 2023. Founded in 2000, it is headquartered in Cardiff, United Kingdom.

Where is BDRX stock listed?

Biodexa Pharmaceuticals Plc trades under the ticker BDRX on NASDAQ.

How can I research BDRX's financials and filings?

Vantafin provides Biodexa Pharmaceuticals Plc's income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the BDRX profile.